Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
Clinical trial NCT04127110 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04127110
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-17
- Primary completion
- 2024-07-31
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.